Peak6 Investments LLC Neurocrine Biosciences Inc Call Options Transaction History

Peak6 Investments LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	SELL	$130.86 - $143.19 $2.29 Million - $2.51 Million	-17,500 Reduced 95.11%	900 $123,000
Q1 2024 May 14, 2024	BUY	$130.4 - $143.74 $2.28 Million - $2.52 Million	17,500 Added 1944.44%	18,400 $2.54 Million
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $74,249 - $92,932	700 Added 350.0%	900 $118,000
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $18,804 - $23,420	200 New	200 $22,000
Q2 2021 Aug 13, 2021	SELL	$89.43 - $102.27 $187,803 - $214,767	-2,100 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $945,755 - $1.29 Million	-10,800 Reduced 83.72%	2,100 $204,000
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $673,120 - $946,050	-7,000 Reduced 35.18%	12,900 $1.24 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $1.28 Million - $1.97 Million	-15,100 Reduced 43.14%	19,900 $2.43 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $2.6 Million - $3.94 Million	34,600 Added 8650.0%	35,000 $3.03 Million
Q4 2018 Feb 13, 2019	SELL	$68.32 - $124.36 $2.86 Million - $5.21 Million	-41,900 Reduced 99.05%	400 $29,000
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $4.18 Million - $5.32 Million	42,300 New	42,300 $5.2 Million

623

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Peak6 Investments LLC with notifications on news.